Antibody Solutions Secures Grant for Challenging Diagnostic Initiative
Summary
The end result is that those RDTs are unable to differentiate between different strains of malaria," explained John Kenney, PhD, co-founder and president of Antibody Solutions. With support from the Gates Foundation, the Antibody Solutions team can avoid that hurdle and focus on discovering better reagents to the target of interest (plasmodium lactate dehydrogenase protein, or pLDH) by approaching it as they would a traditional therapeutic target.Such a comprehensive approach is typically only selected by drug developers pursuing therapeutic candidates; budget and timeline constraints put the pursuit of multiple simultaneous discovery paths out of reach for most diagnostic reagent discovery projects. "This is extremely challenging science, overcoming high sequence homology and conservation of LDH protein from different strains of malaria," Kenney added. But, we can mitigate this risk by applying strategies that weve successfully employed on similar programs for therapeutic candidates. Using its Cellestive antibody discovery platform, the company provides comprehensive project management and technical support in a fee-for-service, pay-as-you-go business model.